Abstract:Background Intra-arterial prourokinase has been shown to be a promising thrombolytic agent in patients with acute ischaemic stroke. Given the global shortage of thrombolytics, we aimed to assess the non-inferiority of intravenous recombinant human prourokinase compared with alteplase in patients with acute ischaemic stroke who were ineligible for or who refused endovascular thrombectomy. Methods PROST-2 was a phase 3, open-label, non-inferiority, randomised controlled trial conducted at 61 hospitals in China. Patients older than 18 years with acute ischaemic stroke, who were ineligible for or who refused endovascular thrombectomy, were randomly assigned in a 1:1 ratio within 4·5 h of stroke onset to receive intravenous recombinant human prourokinase (15 mg bolus followed by 20 mg infusion within 30 min) or intravenous alteplase (0·9 mg per kg, maximum dose 90 mg; 10% bolus followed by remainder as infusion over 60 min). The primary efficacy outcome was the proportion of patients with a modified Rankin Scale score of 0 or 1 at 90 days, assessed via masked review in the intention-to-treat population, with a non-inferiority margin for the risk ratio of 0·93. The primary safety outcome was the incidence of symptomatic intracranial haemorrhage within 36 h. This trial is registered with ClinicalTrials.gov (NCT05700591) and is now completed. Findings Between Jan 29, 2023, and March 14, 2024, 1552 patients were randomly assigned: 775 received recombinant human prourokinase and 777 received alteplase. The primary outcome of a modified Rankin Scale score of 0 or 1 at 90 days was reached by 558 (72·0%) of 775 patients in the recombinant human prourokinase group versus 534 (68·7%) of 777 in the alteplase group (risk ratio 1·04 [95% CI 0·98 to 1·10]; p<0·0001 for non-inferiority). The frequency of symptomatic intracranial haemorrhage within 36 h was lower in the recombinant human prourokinase group than in the alteplase group (two [0·3%] of 770 patients vs ten [1·3%] of 775, risk difference –1·0 percentage points [95% CI –2·1 to –0·1]; p=0·021), as was the incidence of major bleeding at 7 days (four [0·5%] vs 16 [2·1%]; –1·5 percentage points (–2·8 to –0·4); p=0·0072). All-cause mortality within 7 days did not differ between groups (five [0·6%] deaths in the recombinant human prourokinase group vs 13 [1·7%] in the alteplase group; risk difference –1·0 percentage points; 95% CI –2·3 to 0·1]; p=0·060). Interpretation In our trial, recombinant human prourokinase was shown to be non-inferior to alteplase for achieving excellent functional outcome, with no difference between groups in safety endpoints. These findings support the use of recombinant human prourokinase as a viable alternative to alteplase for patients with ischaemic stroke who are eligible for intravenous thrombolysis therapy but ineligible for or who have refused endovascular thrombectomy. Funding Tasly Biopharmaceuticals, National Key R&D Program of China, National Natural Science Foundation of China, Chinese Academy of Medical Sciences Innovation Fund for Medical Sciences, and Beijing Municipal Science & Technology Commission. Translation For the Chinese translation of the abstract see Supplementary Materials section.

Evaluation of the efficacy and safety of recombinant prourokinase in patients with acute myocardial infarction

Urokinase Combined with Liposomal Alprostadil in the Treatment of Acute Myocardial Infarction

Efficacy and Safety of Recombinant Human Prourokinase in Acute Ischemic Stroke: A Phase IIa Randomized Clinical Trial

A clinical study of high-dose urokinase for the treatment of the patients with hypertension induced ventricular hemorrhage

Effects of Intracoronary administration of nitroprusside on no-reflow phenomenon during emergency percutaneous coronary Intervention in patients with acute myocardial infarction

[Efficacy and safety comparison between pro-urokinase and reteplase in the treatment of patients with acute ST elevation myocardial infarction]

Efficacy and Safety of Recombinant Human Prourokinase in the Treatment of Acute Ischemic Stroke Within 4.5 Hours of Stroke Onset: A Phase 3 Randomized Clinical Trial

Safety and Efficacy of Intravenous Recombinant Human Prourokinase for Acute Ischaemic Stroke Within 4·5 H after Stroke Onset (PROST-2): a Phase 3, Open-Label, Non-Inferiority, Randomised Controlled Trial

Effect of recombinant human prourokinase on thrombolysis in a rabbit model of thromboembolic stroke

Study on the changes in the left ventricular diastolic function of the patients with acute myocardial infarction treated with the urokinase thrombolysis therapy within 3 hours or after 3 hours of attack

Thrombolysis with Recombinant Human Prourokinase 4.5-6 h After Acute Ischemic Stroke: A Phase IIa, Randomized, and Open-Label Multicenter Clinical Trial

A randomized study of prourokinase during primary percutaneous coronary intervention in acute ST-segment elevation myocardial infarction

Comparative study on the efficacy and safety of alteplase and urokinase in the treatment of acute cerebral infarction.

Studing of the Special Problems in Thrombolysis Cure of Acute Myocardial Infarction

Comparative study of intravenous thrombolysis with rt-PA and urokinase for patients with acute cerebral infarction

A Multicenter, Randomized,double-Blinded and Placebo-Controlled Study of Acute Brain Infarction Treated by Humanurinary Kallidinogenase

The efficacy and safety of pharmacoinvasive therapy with prourokinase for acute ST-segment elevation myocardial infarction patients with expected long percutaneous coronary intervention-related delay.

RhPro-UK in Acute Ischemic Stroke Within 4.5 H of Stroke Onset Trial-2 (the PROST-2 Study): Rationale and Design of a Multicenter, Prospective, Randomized, Open-Label, Blinded-Endpoint, Controlled Phase 3 Non-Inferiority Trial

Intravenous thrombolysis with urokinase for acute cerebral infarctions(within 6h from symptom onset)

Clinical Study On The Thrombolytic Effect With Different Doses Of Urokinase In Acute Myocardial Infarction

Effects of Intracoronary Pro-urokinase or Tirofiban on Coronary Flow During Primary Percutaneous Coronary Intervention for Acute Myocardial Infarction: A Multi-Center, Placebo-Controlled, Single-Blind, Randomized Clinical Trial